CAR-T Expands to Solid Tumors & Autoimmune Diseases; BAF CAR-T Shows Promising Early Results for Lupus, Compared with Off-the-Shelf CAR-NK Cells

June 28, 2026

University Hospitals USA

Overview

CAR-T cell therapy is expanding its success from hematologic malignancies to solid tumors and autoimmune diseases. Notably, early clinical trial results for BAF CAR-T in lupus are highly promising, suggesting potential applications in rheumatoid arthritis and type 1 diabetes. While off-the-shelf CAR-NK cells offer advantages as a universal donor source, they may be inferior to CAR-T cells in terms of in vivo persistence and proliferation, prompting discussions on optimal applications for each modality.

In Depth

Key Findings

CAR-T cell therapy is extending its groundbreaking success from hematological cancers to solid tumors and autoimmune diseases. As part of this expansion strategy, early clinical trials for BAF CAR-T treatment in lupus, an autoimmune disorder, have yielded exceptionally promising results, opening avenues for potential applications in other autoimmune conditions such as rheumatoid arthritis and type 1 diabetes.

Technical / Clinical Details

CAR-T cell therapy, which genetically modifies a patient’s own T cells to target cancer cells, is now broadening its scope beyond oncology to target pathogenic B cells in autoimmune diseases. Specifically, initial clinical trials of BAF CAR-T therapy for lupus patients have reported significant disease improvement, drawing considerable attention to its efficacy and safety. In parallel, off-the-shelf CAR-NK cells, envisioned as universal donor therapies, offer the substantial advantage of being readily available for multiple patients. However, they are noted to potentially exhibit inferior in vivo proliferation and persistence compared to CAR-T cells. CAR-T cells, with their robust proliferative capacity and long-term persistence, hold the potential to deliver curative effects for refractory diseases.

Background & Context

While CAR-T cell therapy has brought dramatic benefits to patients with relapsed/refractory hematological malignancies, it also presents challenges including high costs, complex manufacturing processes, severe side effects, and limited efficacy in solid tumors. Its application to autoimmune diseases offers new hope for patients unresponsive to conventional immunosuppressive therapies. Furthermore, the development of off-the-shelf cellular therapies is critical for increasing treatment accessibility and reducing manufacturing costs. Understanding the distinct characteristics of CAR-T and CAR-NK and selecting the optimal therapy based on the disease and patient condition will be a key direction for future regenerative medicine.

Strategic Significance & Outlook

The success of CAR-T therapy in autoimmune diseases is expected to accelerate research and development in this field. The promising results of BAF CAR-T in lupus particularly suggest strong potential for application in other B-cell-mediated autoimmune diseases like rheumatoid arthritis and type 1 diabetes. In the solid tumor realm, further technological improvements will likely focus on enhancing CAR-T cell infiltration into the tumor microenvironment and improving their persistence. CAR-NK cell therapies, leveraging their unique safety profile and versatility, are also anticipated for broader application across various diseases. The evolution of these cellular therapies holds the potential to profoundly transform medical paradigms in the coming years.

Source: https://www.uhhospitals.org/for-clinicians/articles-and-news/articles/2026/06/from-lab-to-life-expanding-the-power-of-car-t-cells

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.